On a mobile? 
You are here: Home » Massachusetts » Cambridge
| Neighborhood Info: | Overview, Schools, Events, Economy, Climate, Value Trends, Cost of Living, Crime Rates |
| Real Estate: | Massachusetts Real Estate Database, Massachusetts Homes For Sale, Foreclosures |
| Useful Services: | Home Staging, Real Estate Brokers/Agents, Videographers, Moving Services, Home Inspectors |
U.S. Events Finder
| Cambridge, Massachusetts Event Score |
1051 /100what is this? |
See what sports, music or family events are going on there. We show you events of all kinds: make your selection from the right-hand navigation bar. After you make your selection, please click Apply button.
Conference
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
Targeting the PI3-Kinase Pathway in Cancer |
| Nov 11-14, 2008 at Hyatt Regency Cambridge, Cambridge Massachusetts United States |
| Mutations in genes that encode components of the phosphoinositide 3-kinase (PI3K) pathway are perhaps the most frequent events observed in solid tumors. The PI3K pathway can be activated by overproduction of growth factors or chemokines or by mutations in growth factor receptors, Ras, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. However, progress is being made as several small molecule inhibitors of Class Ia PI3K enzymes have recently entered phase I clinical trials. This AACR Special Conference will assemble prominent investigators to discuss recent advances in this rapidly growing area. Sessions will focus on the basic research which is studying the role of PI3K and related pathways in cancer. Discussions will also explore strategies for determining which patients are |
2009 35th Annual Northeast Bioengineering Conference |
| Apr 3-5, 2009 at Joseph B. Martin Conference Centre, Cambridge Massachusetts United States |
| It is with great pleasure that I encourage and welcome you to attend the 35th Annual Northeast Bioengineering Conference at Harvard April 3rd (Friday) to April 5th (Sunday), 2009. Keeping with the strong tradition of the Northeast Bioengineering Conference, we promise to create a conference allowing for new friendships and the exchange of ideas concerning the latest efforts in bioengineering-related research. Looking forward to your visit, Dr. Jeffrey M. Karp Director of the Laboratory for Advanced Biomaterials & Stem Cell-Based Therapeutics Harvard-MIT Division of Health Sciences and Technology Department of Medicine, Brigham and Women's Hospital Harvard Medical School Room 313, PRB 65 Landsdowne Street Cambridge, MA 02139, USA |
